Robinhood Markets, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Robinhood Markets, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.47B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.95B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.87B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.36B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.82B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $958.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $277.53M | Feb 24, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.88B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($541.00M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($1.03B) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($3.69B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $7.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($106.57M) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $355.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $323.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $349.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $381.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $438.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $52.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $27.70M | Feb 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($157.00M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($852.00M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($885.00M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.88B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.26B | Feb 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.14B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $26.19B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $17.62B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $23.34B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $19.77B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $10.99B | Feb 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.99B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $18.22B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $10.93B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $16.38B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $12.48B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $8.86B | Feb 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.97B | Feb 18, 2025 |
| FY2024 | Dec 31, 2023 | $6.70B | Feb 18, 2025 |
| FY2024 | Dec 31, 2022 | $6.96B | Feb 18, 2025 |
| FY2024 | Dec 31, 2021 | $7.29B | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | ($55.00M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | ($97.00M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | ($21.48M) | Feb 24, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $385.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $179.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $175.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $100.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $101.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Feb 27, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.15B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($4.04B) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($5.45B) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($4.91B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($3.88B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($190.10M) | Feb 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.26B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.33B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $4.84B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $6.34B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $6.25B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.40B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $644.05M | Feb 24, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 229.03M | Feb 24, 2022 |